中国口腔颌面外科杂志 ›› 2026, Vol. 24 ›› Issue (5): 454-460.doi: 10.19438/j.cjoms.2026.05.003

• 讲座 • 上一篇    下一篇

脉管畸形的治疗现状及临床研究进展

成伟1, 王熙鹏1, 张金蕊1, 刘乐2, 邹林峰2, 魏山坡2, 倪鑫1   

  1. 1.首都医科大学附属北京儿童医院,北京 100045;
    2.北京儿童医院保定医院,河北 保定 071030
  • 收稿日期:2025-12-19 修回日期:2026-03-15 出版日期:2026-09-20 发布日期:2026-10-10
  • 通讯作者: 魏山坡,E-mail: bartsherwood002@163.com
  • 作者简介:成伟(1983—),男,博士,副主任医师,E-mail: drchengwei@126.com

The current treatment status and clinical research progress of vascular malformations

Cheng Wei1, Wang Xipeng1, Zhang Jinrui1, Liu Le2, Zou Linfeng2, Wei Shanpo2, Ni Xin1   

  1. 1. Beijing Children's Hospital, Capital Medical University. Beijing 100045;
    2. Baoding Hospital of Beijing Children's Hospital. Baoding 071030, Hebei Province, China
  • Received:2025-12-19 Revised:2026-03-15 Online:2026-09-20 Published:2026-10-10

摘要: 脉管畸形(vascular malformations, VMs)是一类由于血管发育过程中出现异常而导致的血管结构异常性疾病。这些疾病通常发生于出生时或出生后一段时间。脉管畸形常常涉及全身多个系统和器官,治疗难度大,严重影响患者的生活质量。传统的治疗方法包括手术切除、硬化治疗、激光治疗、介入栓塞和药物治疗等。近年来,随着分子生物学研究的深入,针对脉管畸形发病机制的靶向治疗成为研究热点,特别是针对 PI3K/AKT/mTOR 通路和 RAS/RAF/MEK/ERK 通路的靶向药物在临床研究中显示出良好的治疗前景。联合治疗策略、多学科协作治疗模式和个体化治疗策略的应用,也为脉管畸形的治疗提供了新的思路和方法。此外,纳米技术、射频消融、基因治疗等新兴治疗技术的发展,为脉管畸形的治疗带来了新的希望。

关键词: 脉管畸形, 靶向治疗, 信号通路, 新技术

Abstract: Vascular malformations (VMs) refer to a cluster of vascular structural anomalies arising from defects during embryonic vascular development. These abnormalities are typically present at birth or shortly postnatally, while some may remain latent and manifest in later life. As VMs involve multiple systemic organs and present considerable therapeutic challenges, they severely compromise patients' quality of life. Conventional therapeutic modalities include surgical resection, sclerotherapy, laser therapy, interventional embolization, and pharmacotherapy. In recent years, with the advancement of molecular biology research, targeted therapy for the pathogenesis of vascular malformations has become a research hotspot. In particular, targeted drugs against the PI3K/AKT/mTOR pathway and the RAS/RAF/MEK/ERK pathway have demonstrated promising therapeutic prospects in clinical studies. The implementation of combined treatment strategies, multidisciplinary team (MDT) collaboration models, and individualized therapeutic regimens has further offered novel perspectives and approaches for VM management. Additionally, the evolution of emerging technologies such as nanotechnology, radiofrequency ablation, and gene therapy has ushered in new hope for the treatment of VMs.

Key words: Vascular Malformations, Targeted therapy, Signaling pathways, Emerging therapeutic technologies

中图分类号: